Identification of predictive markers in the cerebrospinal fluid of patients with glioblastoma

Introduction . Glioblastoma (GB) is not yet curable despite recent advances in the treatment of other malignant solid tumors. The management GB based solely on histopathological features, imaging tumor and its genomic analysis (somatic mutations isocitrate dehydrogenase genes, methylation status O 6 -methylguanine-DNA methyltransferase gene promoter). To adapt to most evolution, molecular information should be received regularly throughout course therapy. However, tissue often available for diagnosis as disease progresses. In this regard, development less invasive methods, such proteome biological fluids patients, particular interest. Cerebrospinal fluid (CSF) an important source biomarkers monitor presence progression disease. Aim identify proteomic predictive CSF patients with GB. Materials methods During study, samples patients’ samples, high-resolution mass spectrometry, modern biochemical bioinformatic technologies were used. Results For first time, proteomes obtained before 7 days after removal primary was carried out. Potential have been identified. After their validation using open databases, 11 markers (S100A9, S100A8, PLA2G15, PPIB, LTBP2, VIM, LAMB1, STC1, NRP1, COL6A1, HSPA5) selected role mechanisms gliomagenesis assessed. Conclusion. proposed panel can further used test systems assessing effectiveness therapy early detection relapses.